Etanercept in psoriasis treatment.
More recently, lots of new drugs regulating the several steps of immune reaction have been introduced for psoriasis treatment. These include TNF-alpha inhibitors. One of such inhibitors is Etanercept--a monoclonal antibody connected with human IgG1 binding the soluble form of TNF-alpha receptor. We present the literature data concerning the attempts of Etanercept treatment and local and general complications of its use.
Chair and Department of Dermatology, Medical University of Lublin, Lublin, Poland.
Aldona
A
Pietrzak
Grazyna
G
Chodorowska
Janusz
J
Urban
Jacek
J
Roliński
Bogusław
B
Pietrzak
D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept